Dapagliflozin for anemia in lower-risk myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a diabetes medicine called dapagliflozin can help improve anemia (low red blood cell count) in people with lower-risk myelodysplastic syndromes. Myelodysplastic syndromes are a group of blood disorders where the bone marrow doesn't make enough healthy blood cells. The study aims to see if this drug can help you feel better by boosting your blood counts.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of myelodysplastic syndromes (MDS), which is a blood disorder where the bone marrow doesn't make enough healthy blood cells.
- Your MDS is considered low or very low risk (not high risk).
- Your hemoglobin levels (the part of your blood that carries oxygen) are low – below 10 g/dL.
- You have not needed many blood transfusions – no more than 2 bags in the past 8 weeks.
- Your kidneys are working well enough (with a clear filtration rate of 30 or above), and your blood counts meet minimum levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
This study tests a medication called dapagliflozin to see if it can reduce inflammation and improve red blood cell and iron levels in people with type 2 diabetes and chronic kidney disease.
This trial tests whether a diabetes medicine called dapagliflozin can help protect kidney function in people with AL amyloidosis. You must live in Michigan and have stable or improving protein in your urine.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial studies dapagliflozin, a diabetes medicine, to see if it can help people with paroxysmal atrial fibrillation (irregular heart rhythm). If you have both diabetes and this type of AF, the study may offer a chance to improve your heart rhythm and outcomes.
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
Hear when a new Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.